CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Rites report Rs 140 crore profit in Q3FY20
Amir Shaikh
/ Categories: Trending

Rites report Rs 140 crore profit in Q3FY20

Rites reported its third quarter result of FY20 today, in which, its revenue from operations increased by nearly 16 per cent, YoY to Rs 602.6 crore in the quarter. This growth was mainly driven by strong 72 per cent YoY growth in Turnkey construction projects, which accounted for almost 33 per cent of the overall revenue. Revenue from consultancy business (domestic) remained largely flat at Rs 266 crore.

EBITDA for Q3FY20 grew by nearly six per cent YoY to Rs 154.7 crore with a corresponding margin contraction of nearly 230 bps while, EBITDA margin for the quarter was at 25.7 per cent. This was mainly on account of a higher share of low margin Turnkey projects.

Profit after Tax (PAT) in Q3FY20 increased 14 per cent YoY to Rs 139.7 crore.

The board of directors of the company has declared an interim dividend of Rs 4.00 per share. Further, the board of directors have fixed February 18, 2020 (Tuesday) as the record date for the purpose of dividend payment

Previous Article Granules India shines on getting USFDA nod for Colchicine tablets
Next Article NFO Analysis: IDFC Emerging Businesses Fund
Print
1167 Rate this article:
4.5
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR